IHC Marker - Brain Tumour Biopsy with Ki 67 Marker (Proliferative Index): Booking, Price, and Results
About IHC Marker - Brain Tumour Biopsy with Ki 67 Marker (Proliferative Index): Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | Ki-67 Proliferation Index, Ki-67/MIB-1 Labelling Index, Brain Tumour IHC with Ki-67, Proliferative Index Brain Tumour Biopsy |
| Sample Type | Brain tumour tissue (formalin-fixed, paraffin-embedded tissue block from biopsy or surgery) |
| Fasting Required | No |
| Report Time | 5 Days |
| Recommended For | All ages and genders; patients with suspected or confirmed brain tumours requiring histopathological grading |
| Price | Starting at ₹1,920 |
What is an IHC Marker – Brain Tumour Biopsy with Ki 67 Marker (Proliferative Index)?
The IHC marker – brain tumour biopsy with Ki-67 marker (proliferative index) test is a specialised laboratory examination performed on brain tumour tissue. It uses immunohistochemistry (IHC), a technique that applies targeted antibodies to a tissue sample to detect specific proteins in cells. In this test, the protein of interest is Ki-67, a marker of cell division activity.
The test measures how rapidly tumour cells are multiplying, which helps doctors assess the aggressiveness of the tumour. It is also referred to as the Ki-67 proliferation index or the MIB-1 labelling index.
What Does an IHC Marker – Brain Tumour Biopsy with Ki 67 Marker (Proliferative Index) – Measure?
This test analyses two key aspects of the brain tumour tissue. Here is what each component indicates.
| Component | What It Tells Us |
|---|---|
| Ki-67 Protein (MIB-1) | Whether tumour cells are actively dividing, present during active cell growth, absent when cells are at rest |
| Proliferative Index (Labelling Index) | The percentage of Ki-67-positive tumour cells out of all cells counted reflects how fast the tumour is growing |
A higher labelling index means more cells are actively dividing, which is associated with more aggressive tumour behaviour.
Why is an IHC Marker – Brain Tumour Biopsy with Ki 67 Marker (Proliferative Index) Done?
This test is ordered after a brain biopsy or tumour resection to help classify the tumour and guide treatment planning.
Common Symptoms That May Require This Test
A doctor may recommend investigation and subsequent biopsy when a patient presents with symptoms such as the following.
- Persistent or worsening headaches
- Seizures (fits) with no prior history
- Nausea and vomiting without a clear cause
- Visual changes or blurred vision
- Weakness or numbness in limbs or one side of the body
- Changes in personality, mood, or behaviour
- Difficulty with balance, coordination, or speech
Conditions This Test Can Help Detect
Once brain tumour tissue is obtained, the IHC marker – a brain tumour biopsy with a Ki-67 marker test – can assist in evaluating the following conditions.
- Gliomas (tumours arising from glial cells, including astrocytomas, oligodendrogliomas, and glioblastomas) across WHO Grades I to IV
- Meningiomas (tumours from the membranes covering the brain): Ki-67 helps predict the likelihood of recurrence
- Ependymomas and medulloblastomas, particularly in paediatric patients
- Metastatic brain tumours, where cancer has spread to the brain from another organ
- Distinguishing between different tumour types such as astrocytic, oligodendroglial, embryonal, lymphoma, or metastatic lesions
How to Prepare and What to Expect
No special preparation is required for the IHC test itself. However, submitting complete clinical documentation is essential for accurate reporting.
Do You Need to Fast?
No fasting is required. This test is performed on a tissue sample, not on blood or urine. You may eat and drink normally.
Practical Tips Before Your Test
Preparing the right documentation makes a significant difference to reporting accuracy. Please keep the following in mind.
- Bring a detailed clinical history including your symptoms, previous test results, and family history, as this is required for the test
- Bring the paraffin-embedded tissue blocks (FFPE blocks) from your biopsy or surgical procedure
- Include the original histopathology report from the initial tissue examination
- Carry relevant radiological reports such as MRI or CT scan images and reports
- Inform the laboratory of any medications you are currently taking or any known allergies
Step-by-Step Procedure
The IHC marker – brain tumour biopsy with Ki-67 marker test procedure involves two stages: the surgical biopsy and the laboratory processing.
- Before the biopsy, an MRI or CT scan is performed to precisely locate the tumour in the brain.
- In hospital, the patient receives general anaesthesia or sedation. A neurosurgeon drills a small opening in the skull and uses a hollow needle to collect a tissue sample from the tumour.
- The collected tissue is placed in a wide-mouth container with 10% formalin solution to preserve it, then transported to the laboratory under refrigerated conditions (2 to 8 degrees Celsius).
- In the laboratory, the tissue is fixed in formalin, embedded in paraffin wax, and cut into very thin slices placed on microscope slides.
- Specialised antibodies that bind to the Ki-67 protein are applied to the slides using the immunohistochemistry method.
- A neuropathologist examines the stained tissue under a microscope and calculates the Ki-67 labelling index by counting the proportion of positively stained tumour cells.
Factors That Can Affect Accuracy
Several technical and biological factors can influence the test result.
- Quality of tissue fixation and the type of fixative used
- Adequacy of the tissue sample obtained during biopsy
- Technical precision during immunohistochemical processing and antigen retrieval
- Tumour heterogeneity (different areas of the same tumour may show different Ki-67 values)
- Lack of a universally standardised method for counting stained cells across laboratories
- Inadvertent inclusion of non-tumour cells (such as immune cells) in the count
Understanding Your IHC Marker – Brain Tumour Biopsy with Ki 67 Marker (Proliferative Index) Results
Results from this test must always be reviewed alongside imaging reports, clinical history, and the full histopathological findings. The Ki-67 labelling index is one part of a broader diagnostic picture.
| Brain Tumour Type / Grade | Typical Ki-67 Labelling Index | Interpretation |
|---|---|---|
| Low-grade gliomas (WHO Grade I to II) | Less than 1% to 5% | Low proliferation |
| High-grade gliomas (WHO Grade III to IV) | 9% to 30% and above | Higher proliferation |
| Meningiomas | Around 1.8% (median) | Generally slower growing |
| Medulloblastomas | Around 19.8% (median) | High proliferation |
| Grade I Astrocytoma | Around 3.4% (mean) | Low-grade |
| Grade IV Astrocytoma (Glioblastoma) | Around 38.7% (mean) | High-grade, aggressive |
These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain factors may affect how results are interpreted.
- Technical issues such as poor tissue fixation or suboptimal antigen retrieval can alter the staining pattern and affect accuracy.
- Tumour heterogeneity means that a sample taken from one region may not represent the entire tumour, which can lead to underestimation of the overall grade.
- Counting non-tumour cells (such as lymphocytes or macrophages) alongside tumour cells may artificially inflate the labelling index.
How to Maintain Healthy Levels
The Ki-67 index reflects the tumour's own biological characteristics and is not affected by lifestyle choices. General guidance for patients at this stage includes the following.
- Attend all follow-up appointments with your neurosurgeon and oncologist as scheduled.
- Keep a record of your symptoms and report any changes promptly to your treating team.
- Follow the treatment plan recommended by your doctors, which may include surgery, radiotherapy, or other therapies.
Lupin Diagnostics IHC Marker – Brain Tumour Biopsy with Ki 67 Marker (Proliferative Index) Price
The IHC marker – brain tumour biopsy with Ki-67 marker test cost at Lupin Diagnostics starts at ₹1,920. This test requires a visit to a Lupin Diagnostics centre; home collection is not available, as the sample must be a tissue block obtained from a hospital-based surgical or biopsy procedure.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 1920 |
| CHENNAI | 1920 |
| HYDERABAD | 1920 |
| KOLKATA | 1920 |
| NAVI MUMBAI | 1920 |
| PUNE | 1920 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book the IHC marker – brain tumour biopsy with Ki-67 marker test online.
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time to submit your tissue block and clinical documentation.
- Receive your report via email or WhatsApp within 5 days.
Frequently Asked Questions
The Ki-67 labelling index is the proportion of tumour cells that are actively dividing at the time the tissue was collected. It is expressed as a percentage. A higher value indicates that more cells are dividing rapidly, which is associated with more aggressive tumour behaviour. Your doctor will use this figure alongside other findings to grade and classify the tumour.
The tissue sample is collected by a neurosurgeon during a brain biopsy or tumour removal operation in a hospital. The procedure may use image-guided (stereotactic) techniques or open surgery, depending on the location and size of the tumour. The collected tissue is then sent to the laboratory for the IHC marker – the brain tumour biopsy with the Ki-67 marker test procedure.
No special preparation is needed for the IHC test itself. However, you must bring your paraffin-embedded tissue blocks, the original histopathology report, and relevant imaging reports. A detailed clinical history is also required when submitting the sample. If you are about to undergo the biopsy surgery, your neurosurgical team will give you separate pre-operative instructions.
The report is typically delivered within 5 days of the tissue sample being received at the laboratory. This time is needed for tissue processing, IHC staining, and expert pathologist review. Turnaround may vary if additional markers are being tested alongside Ki-67.
A higher Ki-67 proliferation index suggests that tumour cells are dividing more rapidly, which is generally associated with higher-grade, more aggressive tumours. For example, glioblastomas can have a mean Ki-67 value of around 38.7%, whereas low-grade tumours typically show values below 5%. Your oncologist will explain what your specific result means for your care plan.
This test helps determine the type and grade of the tumour, not just whether it is present. The Ki-67 index combined with histopathological findings gives information about how aggressively the tumour is growing, which in turn guides decisions about surgery, radiotherapy, or other treatments. A qualified neuropathologist or oncologist will interpret the full picture.
No. The IHC marker – a brain tumour biopsy with a Ki-67 marker test home collection – is not available. The test requires a formalin-fixed, paraffin-embedded tissue block that can only be obtained through a surgical procedure performed in a hospital. Please visit your nearest Lupin Diagnostics centre to submit your tissue sample and documentation.
IHC Marker - Brain Tumour Biopsy with Ki 67 Marker (Proliferative Index): Booking, Price, and Results
